Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.

[1]  Marion Procter,et al.  Adjuvant Pertuzumab and Trastuzumab in Early HER2‐Positive Breast Cancer , 2017, The New England journal of medicine.

[2]  P. Neven,et al.  The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters , 2016, Oncotarget.

[3]  H. Wildiers,et al.  Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations†. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  S. Hughes,et al.  The impact of low-grade toxicity in older people with cancer undergoing chemotherapy , 2014, British Journal of Cancer.

[5]  H. Wildiers,et al.  International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Sung-Bae Kim,et al.  Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[7]  M. Gnant,et al.  HER2-positive breast cancer: a new piece of the puzzle. , 2014, The Lancet. Oncology.

[8]  J. Baselga,et al.  Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.

[9]  Laura Biganzoli,et al.  Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). , 2012, The Lancet. Oncology.

[10]  Sung-Bae Kim,et al.  Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. , 2012, The New England journal of medicine.

[11]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[12]  D. Lacombe,et al.  Questionnaires and instruments for a multidimensional assessment of the older cancer patient: what clinicians need to know? , 2010, European journal of cancer.

[13]  J. Baselga,et al.  Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort , 2010, The Lancet.

[14]  M. Kiechle,et al.  Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials , 2008, Breast Cancer Research.

[15]  H. Bartelink,et al.  Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. , 2007, The Lancet. Oncology.

[16]  A. Goldhirsch,et al.  Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer , 2006, BMC Cancer.

[17]  A. Goldhirsch,et al.  Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  R. Pazdur,et al.  Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  G. Steger,et al.  Oral vinorelbine in the treatment of advanced breast cancer , 2004 .

[20]  Robert S. Kerbel,et al.  The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.

[21]  H. Cohen,et al.  Barriers to clinical trial participation by older women with breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  D J Sargent,et al.  A flexible design for multiple armed screening trials , 2001, Statistics in medicine.

[23]  R. Wolfe,et al.  A semiparametric model for regression analysis of interval-censored failure time data. , 1985, Biometrics.

[24]  M. Highley,et al.  Pharmacology of Anticancer Drugs in the Elderly Population , 2003, Clinical pharmacokinetics.